177478-32-9 Usage
Molecular Weight
162.19 g/mol The relative molecular mass of 1H-Benzimidazol-4-ol,1-methyl-2-(methylamino)-(9CI), based on its molecular formula, is 162.19 grams per mole.
Structure
Heterocyclic compound The compound has a benzimidazole core, which is a heterocyclic aromatic ring system containing two nitrogen atoms.
Functional Groups
Methyl group, Secondary amine group The compound contains a methyl group (-CH3) and a secondary amine group (-NH-CH3) attached to the benzimidazole core.
Position of Substituents
1-methyl, 2-(methylamino) The methyl group is attached to the first position of the benzimidazole core, while the methylamino group is attached to the second position.
Derivative
Benzimidazole 1H-Benzimidazol-4-ol,1-methyl-2-(methylamino)-(9CI) is a derivative of the parent compound benzimidazole, which means it is structurally similar but has additional functional groups.
Applications
Pharmaceuticals, Organic Synthesis, Material Science Due to its unique structure and potential reactivity, 1H-Benzimidazol-4-ol,1-methyl-2-(methylamino)-(9CI) may have various applications in these fields.
Safety Precautions
Handle with care, follow proper safety protocols and guidelines It is important to use 1H-Benzimidazol-4-ol,1-methyl-2-(methylamino)-(9CI) responsibly to prevent accidents or harmful effects.
Check Digit Verification of cas no
The CAS Registry Mumber 177478-32-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,7,4,7 and 8 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 177478-32:
(8*1)+(7*7)+(6*7)+(5*4)+(4*7)+(3*8)+(2*3)+(1*2)=179
179 % 10 = 9
So 177478-32-9 is a valid CAS Registry Number.
177478-32-9Relevant articles and documents
Benzimidazole compounds as bradykinin antagonists
-
, (2008/06/13)
PCT No. PCT/JP95/01478 Sec. 371 Date Feb. 3, 1997 Sec. 102(e) Date Feb. 3, 1997 PCT Filed Jul. 25, 1995 PCT Pub. No. WO96/04251 PCT Pub. Date Feb. 15, 1996This invention relates to a heterocyclic compound of the formula: wherein a group of the formula: is a group of the formula: etc., X is O, S or N-R5, R1 is lower alkyl, etc., R5 is hydrogen, lower alkyl, etc., R2 is hydrogen, halogen, lower alkyl, etc., R3 is halogen, lower alkyl, etc., R4 is amino optionally having suitable substituent(s), and A is lower alkylene, and a salt thereof, to processes for preparation thereof, and to a pharmaceutical composition comprising the same for the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a]pyridine moiety
Abe, Yoshito,Kayakiri, Hiroshi,Satoh, Shigeki,Inoue, Takayuki,Sawada, Yuki,Inamura, Noriaki,Asano, Masayuki,Aramori, Ichiro,Hatori, Chie,Sawai, Hiroe,Oku, Teruo,Tanaka, Hirokazu
, p. 4062 - 4079 (2007/10/03)
Recently we reported on overcoming the species difference of our first orally active non-peptide bradykinin (BK) B2 receptor antagonists, incorporating an 8-[[3-(N-acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]- 3-halo-2-methylimidazo[1,2-α]
